PFE Latest News

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

Press ReleaseN/A

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Press ReleaseN/A

NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Press ReleaseN/A

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC (“

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

Press ReleaseN/A

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazopari

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Press ReleaseN/A

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating